Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Akili Interactive Labs

Evaluate

Thumbnail
March 20, 2023

Pear sets out its stall for potential sale

Thumbnail
February 06, 2023

The slow death of the medtech Spac deal

The remarkable thing is that these tie-ups are still occurring, so atrocious is their track record.

Article image
Vantage logo
October 07, 2022

Nektar and Puretech make strange bedfellows

It is hard to see a combination of the two businesses as much beyond a defensive move in troubled times.

Article image
Vantage logo
September 20, 2022

More hard knocks for the blank cheque space

Article image
Vantage logo
August 18, 2022

Better Therapeutics banks on data and partnerships

But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.

Article image
Vantage logo
March 01, 2022

The uncertain future of medtech Spac deals

Article image
Vantage logo
January 26, 2022

Akili plays the Spac game for $1bn

But, judging by similar transactions, the valuation might not stay that high for long.

Article image
Vantage logo
September 29, 2021

Akili and Shionogi find the clinical game hard to play

Article image
Vantage logo
August 17, 2021

How long will the good times roll for medtech?

The entry of non-traditional funders – and the availability of non-traditional exits – has altered medtech, though probably only temporarily.

Article image
Vantage logo
July 09, 2021

Medtech venture funding hits new heights

Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.

Article image
Vantage logo
December 03, 2020

Prescription apps take off during lockdown

Digital therapeutics are going from strength to strength during the pandemic.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up